Evidence map›Paper›PMID 37355611›Full record

ArticleHarm reduction journal2023

Intersections between syndemic conditions and stages along the continuum of overdose risk among women who inject drugs in Mexicali, Mexico.

Pablo Gonzalez-Nieto, Anabel Salimian, Jaime Arredondo, Lourdes Angulo, Alejandra García de Loera, Said Slim, Steve Shoptaw, Mary C Cambou, Eileen V Pitpitan, David Goodman-Meza

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Pablo Gonzalez-NietoIntegración Social Verter, A.C., Calle José Azueta 230, Primera, 21100, Mexicali, BC, Mexico.
Anabel SalimianDepartment of Medicine, David Geffen School of Medicine at UCLA, 10833, Le Conte Ave, CHS 52-215, Los Angeles, CA, 90095, USA.
Jaime ArredondoIntegración Social Verter, A.C., Calle José Azueta 230, Primera, 21100, Mexicali, BC, Mexico.
Lourdes AnguloIntegración Social Verter, A.C., Calle José Azueta 230, Primera, 21100, Mexicali, BC, Mexico.
Alejandra García de LoeraUniversidad Autónoma de Aguascalientes (UAA), Avenida Universidad #940, 20100, Aguascalientes, AGS, Mexico.
Said SlimIntegración Social Verter, A.C., Calle José Azueta 230, Primera, 21100, Mexicali, BC, Mexico.
Steve ShoptawDepartment of Family Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.
Mary C CambouDepartment of Medicine, David Geffen School of Medicine at UCLA, 10833, Le Conte Ave, CHS 52-215, Los Angeles, CA, 90095, USA.
Eileen V PitpitanSchool of Social Work, San Diego State University, Hepner Hall Room 119, 5500 Campanile Drive, San Diego, CA, 92182-4119, USA.
David Goodman-MezaDepartment of Medicine, David Geffen School of Medicine at UCLA, 10833, Le Conte Ave, CHS 52-215, Los Angeles, CA, 90095, USA. dgoodman@mednet.ucla.edu.
University of California, Los Angeles · USCanadian Institute for Advanced Research · CAAutonomous University of Aguascalientes · MXSan Diego State University · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
Postdoctoral Training in Global AIDS Prevention ResearchT32MH080634 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Pamina Mae Gorbach · 2007 to 2026
$6.4M
Using data science to measure the impact of opioid agonist therapy in patients admitted with Staphylococcus aureus bloodstream infectionsK08DA048163 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOODMAN, DAVID · 2019 to 2023
$1.0M
NCATS NIH HHS UL1 TR001442NCATS NIH HHS UL1 TR001881NIAID NIH HHS P30 AI028697NIAID NIH HHS P30 AI036214NIDA NIH HHS K08 DA048163NIDA NIH HHS K08DA048163NIMH NIH HHS P30 MH058107NIMH NIH HHS P30MH58107NIMH NIH HHS T32 MH080634NIMH NIH HHS T32MH080634
6 · The paper itself

Abstract

backgroundResearch on women who inject drugs is scarce in low- and middle-income countries. Women experience unique harms such as sexism and sexual violence which translate into negative health outcomes. The present work aims to provide insight into the experiences of women who inject drugs at the US-Mexico border to identify social and health-related risk factors for overdose to guide harm reduction interventions across the Global South.

methodsWe recruited 25 women ≥ 18 years of age accessing harm reduction and sexual health services at a non-governmental harm reduction organization, "Verter", in Mexicali, Mexico. We employed purposeful sampling to recruit women who inject drugs who met eligibility criteria. We collected quantitative survey data and in-depth interview data. Analyses of both data sources involved the examination of descriptive statistics and thematic analysis, respectively, and were guided by the syndemic and continuum of overdose risk frameworks.

resultsSurvey data demonstrated reports of initiating injection drug use at a young age, experiencing homelessness, engaging in sex work, being rejected by family members, experiencing physical violence, injecting in public spaces, and experiencing repeated overdose events. Interview data provided evidence of stigma and discrimination toward women, a lack of safe spaces and support systems, risk of overdose-related harms, sexual violence, and the overall need for harm reduction services.

conclusionWomen who inject drugs in Mexicali describe experiences of violence, overdose, and public injecting. Women are particularly vulnerable in the Mexicali context, as this area faces a noticeable lack of health and social services. Evidenced-based harm reduction strategies such as safe consumption sites and overdose prevention strategies (e.g., naloxone distribution and training) may benefit this population. Evidence from local organizations could help close the gap in service provision in low-resource settings like Mexico, where government action is almost nonexistent.

Indexed as

Drug OverdoseSubstance Abuse, IntravenousFemaleHumansMexicoRisk FactorsSyndemicLatin AmericaMexicoOverdosePeople who inject drugsSafe consumption siteStigmaSubstance useViolenceWomen

Identifiers

PMID37355611
PMCPMC10290314
OpenAlexW4381943705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.